Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2015, Article ID 635858, 13 pages
http://dx.doi.org/10.1155/2015/635858
Research Article

Shenqi Fuzheng Injection Combined with Chemotherapy for Breast Cancer: A Meta-Analysis of Randomized Controlled Trials

1Medical College, Jinan University, 601 Huangpu West Avenue, Guangzhou, Guangdong 510632, China
2The First Affiliated Hospital of Jinan University, 601 Huangpu West Avenue, Guangzhou, Guangdong 510632, China
3Institute of Biomedicine and Department of Cellular Biology, Jinan University, 601 Huangpu West Avenue, Guangzhou, Guangdong 510632, China
4Hangzhou Iron and Steel Company Worker Hospital, 1 Kangjian Road, Gongye Area, Hangzhou, Zhejiang 310022, China

Received 13 May 2015; Accepted 11 August 2015

Academic Editor: Seong-Gyu Ko

Copyright © 2015 Yanhong Lv et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. Hong and E. Dong, “The past, present and future of breast cancer research in China,” Cancer Letters, vol. 351, no. 1, pp. 1–5, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. Z. Q. Tao, A. Shi, C. Lu, T. Song, Z. G. Zhang, and J. Zhao, “Breast cancer: epidemiology and etiology,” Cell Biochemistry and Biophysics, vol. 72, no. 2, pp. 333–338, 2015. View at Publisher · View at Google Scholar
  3. J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers, and D. Parkin, GLOBOCAN 2008 V1. 2, Cancer Incidence and Mortality Worldwide, IARC Cancer Base No. 10, IARC, 2014.
  4. S. Alipour, R. Omranipour, I. Jahanzad, and K. Bagheri, “Very young breast cancer in a referral center in Tehran, Iran; review of 55 cases aged 25 or less throughout 33 years,” Asian Pacific Journal of Cancer Prevention, vol. 14, no. 11, pp. 6529–6532, 2014. View at Google Scholar · View at Scopus
  5. A. Keramatinia, S. H. Mousavi-Jarrahi, M. Hiteh, and A. Mosavi-Jarrahi, “Trends in incidence of breast cancer among women under 40 in Asia,” Asian Pacific Journal of Cancer Prevention, vol. 15, no. 3, pp. 1387–1390, 2014. View at Google Scholar
  6. D. R. Youlden, S. M. Cramb, N. A. M. Dunn, J. M. Muller, C. M. Pyke, and P. D. Baade, “The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality,” Cancer Epidemiology, vol. 36, no. 3, pp. 237–248, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. A. J. Montero, S. Eapen, B. Gorin, and P. Adler, “The economic burden of metastatic breast cancer: a U.S. Managed care perspective,” Breast Cancer Research and Treatment, vol. 134, no. 2, pp. 815–822, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. B. Herron, A. Herron, K. Howell, D. Chin, and L. Roads, “A review of radiation therapy's role in early-stage breast cancer and an introduction to electronic brachytherapy,” in Cancer Treatment—Conventional and Innovative Approaches, chapter 10, InTech, Rijeka, Croatia, 2013. View at Publisher · View at Google Scholar
  9. C.-S. Cheng, Z. Wang, and J. Chen, “Targeting FASN in breast cancer and the discovery of promising inhibitors from natural products derived from traditional Chinese medicine,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 232946, 16 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. M. K. Doherty and P. G. Morris, “Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy,” International Journal of Women's Health, vol. 7, pp. 47–58, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Shajahan-Haq, M. Cheema, and R. Clarke, “Application of metabolomics in drug resistant breast cancer research,” Metabolites, vol. 5, no. 1, pp. 100–118, 2015. View at Publisher · View at Google Scholar
  12. L. F. Hutchins, S. J. Green, P. M. Ravdin et al., “Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102,” Journal of Clinical Oncology, vol. 23, no. 33, pp. 8313–8321, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. W. Zhang and Y. Gu, “Research progress on cell apoptosis and tumor chemotherapy,” Journal of Medical Review, vol. 19, no. 3, 24 pages, 2013. View at Google Scholar
  14. L. Lv and X. Song, “Research progress of immune adjust molecules in the regulation of Chemotherapy sensitivity to tumor,” Chinese Journal of Clinical Oncology, vol. 41, no. 24, pp. 1597–1601, 2014. View at Google Scholar
  15. X.-F. Sun, Y.-T. Pei, Q.-W. Yin, M.-S. Wu, and G.-T. Yang, “Application of Aidi injection in the bronchial artery infused neo-adjuvant chemotherapy for stage III a non-small cell lung cancer before surgical operation,” Chinese Journal of Integrative Medicine, vol. 16, no. 6, pp. 537–541, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. Z. Dai, X. Wang, H. Kang et al., “Clinical effects of Shenqi Fuzheng Injection in the neoadjuvant chemotherapy for local advanced breast cancer and the effects on T-lymphocyte subsets,” Journal of Traditional Chinese Medicine, vol. 28, no. 1, pp. 34–38, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Shaw, “Toxicological risks of Chinese herbs,” Planta Medica, vol. 76, no. 17, pp. 2012–2018, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Lechner, I. Steirer, B. Brinkhaus et al., “Efficacy of individualized Chinese herbal medication in osteoarthrosis of hip and knee: a double-blind, randomized-controlled clinical study,” The Journal of Alternative and Complementary Medicine, vol. 17, no. 6, pp. 539–547, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. B. N. Zhang, “The Ministry of health medical administration department ‘breast cancer diagnosis and treatment standard (2011 Edition)’ a brief description,” Chinese Journal of Minimally Invasive Surgery, vol. 12, no. 12, pp. 1057–1058, 2011. View at Google Scholar
  20. A. R. Jadad, R. A. Moore, D. Carroll et al., “Assessing the quality of reports of randomized clinical trials: is blinding necessary?” Controlled Clinical Trials, vol. 17, no. 1, pp. 1–12, 1996. View at Publisher · View at Google Scholar · View at Scopus
  21. J. P. T. Higgins, D. G. Altman, P. C. Gøtzsche et al., “The Cochrane Collaboration's tool for assessing risk of bias in randomised trials,” British Medical Journal, vol. 343, Article ID d5928, 2011. View at Publisher · View at Google Scholar
  22. F. Xie, “Clinical analysis of Shenqi fuzheng injection combined with chemotherapy in the treatment of breast cancer,” Guide of China Medicine, vol. 1, no. 30, pp. 19–20, 2014. View at Google Scholar
  23. F. Liang, Q. S. Zhang, L. J. Zhang, G. C. Xing, and J. M. Li, “Meta analysis about the effect of Shenqi fuzheng injection combined with chemotherapy in the treatment of breast cancer,” China Practical Medical, vol. 9, no. 3, pp. 175–176, 2014. View at Google Scholar
  24. Q. Zhang, J. B. Cai, X. Chen, W. B. Shi, L. J. Yang, and J. Zhou, “Effect of Shenqi fuzheng injection combined with chemotherapy in the treatment of advanced triple negative breast cancer with 32 patients,” China Pharmacist, vol. 16, no. 12, pp. 1866–1867, 2013. View at Google Scholar
  25. A. Kawuli and A. Maimaiti, “Effect observation of Shenqi fuzheng injection combined with chemotherapy in the treatment of advanced breast cancer,” Guide of China Medicine, vol. 9, no. 23, pp. 311–312, 2011. View at Google Scholar
  26. H. H. Xu and D. J. Wei, “Clinical study of Shenqi fuzheng injection alleviates cardiac toxicity of chemotherapy TA in breast cancer,” Chinese Community Doctors, vol. 12, no. 36, p. 130, 2010. View at Google Scholar
  27. Z. F. Huang, J. S. Wei, H. Z. Li, Z. Q. Tan, Z. J. Zhang, and C. Chen, “Clinical observation of Shenqi Fuzheng injection combined with chemotherapy in the treatment of 30 advanced breast cancer patients,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 28, no. 2, pp. 152–154, 2008. View at Google Scholar
  28. J. W. Yuan, C. B. Kong, G. Q. Kang, X. F. Liu, and S. J. Yang, “Effect of Shenqi fuzheng injection on breast cancer cell immune function in neoadjuvant chemotherapy,” Lishizhen Medicine and Materia Research, vol. 19, no. 5, pp. 1099–1100, 2008. View at Google Scholar
  29. K. Zhu, K. Li, C. X. Dang, and D. M. Chang, “Effect of Shenqi fuzheng injection combined with CEF chemotherapy on immune function in patients with breast cancer after operation,” Chinese Journal of Clinical Oncology, vol. 35, no. 14, pp. 808–809, 2008. View at Google Scholar
  30. Z. C. Qiu, “Clinical observation of Shenqi fuzheng injection combined with chemotherapy in the treatment of advanced breast cancer,” Journal of Liaoning University of Traditional Chinese Medicine, vol. 12, no. 11, pp. 174–175, 2010. View at Google Scholar
  31. Z. J. Dai, X. J. Wang, H. F. Kang et al., “Clinical observation to the effect and adverse reaction of Shenqi Fuzheng injection in the neoadjuvant chemotherapy of breast,” Adverse Drug Reactions Journal, vol. 9, no. 1, pp. 10–14, 2007. View at Google Scholar
  32. F. Chen and H. Lin, “Clinical observation of Shenqi Fuzheng injection in adjuvant chemotherapy for breast cancer,” Strait Pharmaceutical Journal, vol. 19, no. 12, pp. 75–76, 2007. View at Google Scholar
  33. S. M. Wang, Y. W. Guo, and G. S. Huang, “Application of Shenqi fuzheng injection in the treatment of adjuvant chemotherapy for breast cancer,” China Medical Herald, vol. 3, no. 17, 124 pages, 2006. View at Google Scholar
  34. H. W. Xiao, “Effect of Shenqi fuzheng injection combined with FEC chemotherapy in the treatment of breast cancer,” The Journal of Medical Theory and Practice, vol. 18, no. 8, pp. 885–886, 2005. View at Google Scholar
  35. X. L. Li, Q. Y. Tian, and W. J. Ma, “Clinical observation of SFI combined with chemotherapy in the treatment of advanced breast cancer,” Journal of Modern Oncology, vol. 12, no. 6, pp. 574–575, 2004. View at Google Scholar
  36. Y. Z. Cui, S. J. Zhang, Y. G. Han, and X. W. Liang, “Clinical observation of Shenqi fuzheng injection in the prevention of cardio toxicity from anthracycline,” Hebei Medical Journal, vol. 33, no. 11, pp. 1685–1686, 2011. View at Google Scholar
  37. Y. Q. Li and S. P. Peng, “Effect of SFI combined with chemotherapy in the treatment of 35 postoperative breast cancer patients,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 22, no. 11, 827 pages, 2002. View at Google Scholar
  38. Z. J. Song, “Effect-enhancing and toxicity-reducing clinical observation of Shenqi fuzheng injection in the treatment of postoperative chemotherapy for breast cancer,” Chinese Journal for Clinicians, vol. 32, no. 9, pp. 62–63, 2004. View at Google Scholar
  39. M. Wu, “Clinical effective observation of Shenqi Fuzheng injection in adjuvant treatment of 36 postoperative breast cancer patients,” Gems of Health, no. 11, 2012. View at Google Scholar
  40. E.-F. Solomayer, M. Feuerer, L. Bai et al., “Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer,” Clinical Cancer Research, vol. 9, no. 1, pp. 174–180, 2003. View at Google Scholar · View at Scopus
  41. V. Mandilaras, N. Bouganim, J. Spayne et al., “Concurrent chemoradiotherapy for locally advanced breast cancer—time for a new paradigm?” Current Oncology, vol. 22, no. 1, pp. 25–32, 2015. View at Publisher · View at Google Scholar · View at Scopus
  42. S. R. Zhuang, H. F. Chiu, S. L. Chen et al., “Effects of a Chinese medical herbs complex on cellular immunity and toxicity-related conditions of breast cancer patients,” British Journal of Nutrition, vol. 107, no. 5, pp. 712–718, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Wang, X. Tong, P. Li, H. Cao, and W. Su, “Immuno-enhancement effects of Shenqi Fuzheng Injection on cyclophosphamide-induced immunosuppressant in Balb/c mice,” Journal of Ethnopharmacology, vol. 139, no. 3, pp. 788–795, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. L. Pan, “Practical road of ‘the numeral turn Chinese herbal medicine’ for Shenqi fuzheng injection,” Journal of China Prescription Drug, vol. 1, no. 82, pp. 37–39, 2009. View at Google Scholar
  45. Z. H. Zhong, “Dictate history: a national new medicine that come from experiential prescription,” Journal of China Prescription Drug, vol. 1, no. 82, pp. 33–36, 2009. View at Google Scholar
  46. C. Xu, Y. Liu, G. Yuan, and M. Guan, “The contribution of side chains to antitumor activity of a polysaccharide from Codonopsis pilosula,” International Journal of Biological Macromolecules, vol. 50, no. 4, pp. 891–894, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Fu, Z. H. Wang, L. F. Huang et al., “Review of the botanical characteristics, phytochemistry, and pharmacology of Astragalus membranaceus (Huangqi),” Phytotherapy Research, vol. 28, no. 9, pp. 1275–1283, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. J. F. Bi, W. W. Sun, and P. Wang, “Analyze the main problems of meta-analysis literature about Chinese medicine,” Journal of Shandong University of Traditional Chinese Medicine, vol. 35, no. 4, pp. 302–303, 2011. View at Google Scholar